Bleeding News and Research

RSS

Boehringer Ingelheim to announce positive results from its RE-COVER study

Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.

2 Dec 2009

RapidArc radiotherapy technology delivers highly-precise IMRT treatment

Former New Jersey Assemblyman Francis Bodine was surprised and delighted when his radiotherapy treatment sessions for prostate cancer went from about 20 minutes each day to less than five.

2 Dec 2009

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

Masimo Rainbow SET Acoustic Monitoring receives FDA clearance

Masimo, the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, today announced FDA clearance of its latest innovation -- Masimo Rainbow SET Acoustic Monitoring(TM)( -- )providing noninvasive and continuous respiration rate (RRa(TM)) that is accurate, easy-to-use, and enhances patient compliance.

1 Dec 2009

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

1 Dec 2009

Given Imaging's PillCam SB wireless capsule endoscopy effective in treating GI patients

Given Imaging Ltd., the global leader in patient-friendly GI diagnostic and monitoring solutions, today announced that three new studies demonstrate that PillCam® SB endoscopy has a clear impact on how physicians manage GI patients, including those patients suspected of having Crohn's disease. The studies were presented at the Gastro 2009 conference taking place in London from November 21 to 25.

25 Nov 2009

Mayo Clinic Women's HealthSource offers tips to reduce gas

Passing gas -- flatulence -- is normal and happens to everyone. But for some people, excessive gas and pain interfere with normal activities. The November issue of Mayo Clinic Women's HealthSource offers tips to reduce gas.

24 Nov 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

Opinion: China forced abortions; U.S. work in Africa; foreign aid; Uganda legislation

"One of the few incontrovertible assertions one can reasonably make is that no one supports forced abortion," syndicated columnist Kathleen Parker writes in a Detroit News opinion piece that examines reports of "coerced abortions" and involuntary sterilizations in China.

23 Nov 2009

UAB performs complicated eye reconstruction surgery

Singh and the team were practicing in Bundi, in northwestern India. It was a common drill, the coach hitting a golf ball at Singh, trying to keep the ball low. A field hockey ball is about the size of a baseball, and by trying to stop the much smaller and faster moving golf ball, it was thought a goalie could improve his reflexes and timing. Only this time the coach hit the ball too high.

21 Nov 2009

Twenty-five design teams compete in Brown School of Engineering Elevator Pitch Contest

Twenty-five Senior Design Teams competed for prizes Thursday night at Rice University's Brown School of Engineering Elevator Pitch Contest. The purpose of the contest was to get students to think about the commercial viability of their designs before building prototypes. Teams had 60 seconds to pitch their design project to an audience of local venture capitalists and business leaders.

20 Nov 2009

"Micro-endoscopes" to detect tumors at earlier stages being developed

Traditional endoscopes provide a peek inside patients' bodies. Now, a University of Florida engineering researcher is designing ones capable of a full inspection.

19 Nov 2009

Study: EP4 agonist may reduce gastric bleeding and inflammation

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding.

19 Nov 2009

Medspira to manufacture and market Mayo Clinic developed products and technologies

Medspira, and Mayo Clinic have entered into an agreement to commercialize, manufacture and market several Mayo Clinic developed products and technologies invented by Mayo physicians and scientists.

19 Nov 2009

Drug interaction between clopidogrel and omeprazole: New safety information

Today the FDA notified healthcare professionals of new safety information concerning a drug interaction between clopidogrel, an anti-clotting medication, and omeprazole, a proton pump inhibitor (PPI) used to reduce stomach acid.

18 Nov 2009

Uniformly structured radiological test result reporting decreases the accuracy of the reports

As many software companies work to create programs that will give uniform structure to the way radiological test results are reported, a new study by researchers at Wake Forest University School of Medicine shows that such a system does not improve, but rather decreases the completeness and accuracy of the reports.

17 Nov 2009

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

A new, reversible antiplatelet drug did not demonstrate superiority over a current irreversible one in reducing the composite of death, heart attack or ischemia-related revascularization in the 48 hours after angioplasty, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

17 Nov 2009

FDA's BPAC renders positive opinion on Phase III clinical trial of INTERCEPT Blood System

Cerus Corporation announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.

17 Nov 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

Self-care tips for hemorrhoids from Mayo Clinic

By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem.

16 Nov 2009